Therefore, utilizing the highly expressed LILRB4 molecule to recognize pathogenic PBs/PCs and target pathogenic PBs/PCs could provide a new avenue for effective treatment of SLE. This evidence concerns the gene LILRB4 and systemic lupus erythematosus.